Embecta (EMBC) Aperçu de l'action
Embecta Corp. est une société de dispositifs médicaux qui propose des solutions pour améliorer la santé et le bien-être des personnes atteintes de diabète aux États-Unis et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 0/6 |
| Performances passées | 4/6 |
| Santé financière | 0/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
EMBC Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Embecta Corp. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$3.24 |
| Plus haut sur 52 semaines | US$15.55 |
| Plus bas sur 52 semaines | US$2.77 |
| Bêta | 0.81 |
| Variation sur 1 mois | 0.93% |
| Variation sur 3 mois | -63.39% |
| Variation sur 1 an | -69.05% |
| Variation sur 3 ans | -84.82% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | n/a |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 29
EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns
Analysts have reduced their price target for Embecta to $3 from $11, citing updated views on medtech valuations, regulatory and utilization concerns, and a reset in expectations for revenue growth, profit margins, and forward P/E multiples. Analyst Commentary Recent Street research on Embecta points to a more cautious stance, with multiple bearish analysts trimming price targets and reassessing the stock in light of sector wide pressures in medical technology and concerns around utilization and regulation.
Mise à jour du récit • Jun 15
EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential
Embecta's analyst price targets have been sharply reset lower, with one major firm cutting its view to $3 from $11 as analysts factor in what they see as tougher medtech valuations tied to slower product cycles, healthcare utilization concerns, inflation pressures after recent conflicts, and investor preference for data center exposure over healthcare. Analyst Commentary Recent research commentary around Embecta has centered on recalibrating expectations for medtech stocks in light of slower product cycles, healthcare utilization questions, and cost pressures tied to inflation.Mise à jour du récit • Jun 01
EMBC: Sector Reset And Buybacks Will Shape Future Upside Potential
The Street’s view on Embecta has reset sharply, with the average analyst price target moving from about $11 to around $5 as analysts recalibrate for lower P/E assumptions and sector wide pressure on medtech valuations. This pressure is tied to slower product cycles, utilization concerns, higher inflation, and capital flowing to data centers instead of healthcare.Recent updates
Mise à jour du récit • Jun 29
EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns
Analysts have reduced their price target for Embecta to $3 from $11, citing updated views on medtech valuations, regulatory and utilization concerns, and a reset in expectations for revenue growth, profit margins, and forward P/E multiples. Analyst Commentary Recent Street research on Embecta points to a more cautious stance, with multiple bearish analysts trimming price targets and reassessing the stock in light of sector wide pressures in medical technology and concerns around utilization and regulation.Mise à jour du récit • Jun 15
EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential
Embecta's analyst price targets have been sharply reset lower, with one major firm cutting its view to $3 from $11 as analysts factor in what they see as tougher medtech valuations tied to slower product cycles, healthcare utilization concerns, inflation pressures after recent conflicts, and investor preference for data center exposure over healthcare. Analyst Commentary Recent research commentary around Embecta has centered on recalibrating expectations for medtech stocks in light of slower product cycles, healthcare utilization questions, and cost pressures tied to inflation.Mise à jour du récit • Jun 01
EMBC: Sector Reset And Buybacks Will Shape Future Upside Potential
The Street’s view on Embecta has reset sharply, with the average analyst price target moving from about $11 to around $5 as analysts recalibrate for lower P/E assumptions and sector wide pressure on medtech valuations. This pressure is tied to slower product cycles, utilization concerns, higher inflation, and capital flowing to data centers instead of healthcare.Mise à jour du récit • May 16
EMBC: Reset Expectations And Capital Returns Will Shape The Bullish Case
Analysts have reset Embecta's fair value estimate from $25 to $11, reflecting lower price targets after recent cuts from firms that cited updated views on growth, profitability and risk. Analyst Commentary Recent research updates point to a more cautious stance on Embecta's valuation, with several firms lowering their price targets and, in at least one case, issuing a downgrade.
Mise à jour du récit • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Mise à jour du récit • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Seeking Alpha • Mar 19
Embecta: An Interesting Deal At An Interesting Time
Summary Embecta trades at multi-year lows due to GLP-1 overhang and flat sales but maintains strong margins and a >6% dividend yield. Embecta's £150M acquisition of Owen Mumford adds higher-growth exposure, is strategically sound, and is priced at a reasonable 1.4–2x sales multiple. Leverage will rise to 3.3x EBITDA post-deal but appears manageable given stable cash flows and robust profitability. I am cautiously upbeat, seeing deep value at 3x earnings, but prefer a small position due to near-term dilution and leverage concerns. Read the full article on Seeking AlphaMise à jour du récit • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Article d’analyse • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Article d’analyse • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Article d’analyse • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Mise à jour du récit • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Mise à jour du récit • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Article d’analyse • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Mise à jour du récit • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Mise à jour du récit • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Article d’analyse • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Article d’analyse • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Article d’analyse • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Article d’analyse • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Mise à jour du récit • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Article d’analyse • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Article d’analyse • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Article d’analyse • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Article d’analyse • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaArticle d’analyse • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Article d’analyse • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Article d’analyse • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
Nouveau récit • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Article d’analyse • Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Article d’analyse • Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 3.1% to close at US$14.82 following the...Article d’analyse • Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Rendement pour les actionnaires
| EMBC | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -3.3% | -1.3% | 0.7% |
| 1Y | -69.1% | -18.6% | 20.6% |
Rendement vs Industrie: EMBC a sous-performé le secteur US Medical Equipment qui a rapporté -18.6 % au cours de l'année écoulée.
Rendement vs marché: EMBC a sous-performé le marché US qui a rapporté 20.6 % au cours de l'année écoulée.
Volatilité des prix
| EMBC volatility | |
|---|---|
| EMBC Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de EMBC a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de EMBC est passée de 11% à 18% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1924 | 1,850 | Dev Kurdikar | www.embecta.com |
Embecta Corp. est une société de dispositifs médicaux qui fournit des solutions pour améliorer la santé et le bien-être des personnes atteintes de diabète aux États-Unis et dans le monde. Les produits de la société comprennent des aiguilles de stylo, des seringues et des dispositifs d'injection de sécurité, ainsi que des applications numériques pour aider les personnes à gérer leur diabète. Elle vend principalement ses produits à des grossistes et à des distributeurs.
Embecta Corp. Résumé des fondamentaux
| EMBC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$188.66m |
| Bénéfices(TTM) | US$111.90m |
| Recettes(TTM) | US$1.04b |
1.7x
Ratio P/E0.2x
Ratio P/SLe site EMBC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| EMBC compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.04b |
| Coût des recettes | US$397.00m |
| Marge brute | US$645.50m |
| Autres dépenses | US$533.60m |
| Les revenus | US$111.90m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.89 |
| Marge brute | 61.92% |
| Marge bénéficiaire nette | 10.73% |
| Ratio dettes/capitaux propres | -211.9% |
Quelles ont été les performances à long terme de EMBC?
Voir les performances historiques et les comparaisonsDividendes
1.2%
Rendement actuel des dividendes32%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 22:10 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Embecta Corp. est couverte par 6 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |